Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing the previous v3.6.1 as the study document version. This appears to be an administrative update that does not modify core study content.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.1, signaling a small build update. The study content and visible information remain unchanged.SummaryDifference0.0%

- Check33 days agoChange DetectedThe study record now shows recruitment is closed to new participants, and new recruitment sites (e.g., Hunan Cancer hospital 1 and University College Hospital) along with updated navigation items were added to aid readers in understanding how to join and read the study.SummaryDifference0.3%

- Check41 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a new version of the study documentation has been issued for the record.SummaryDifference0.0%

- Check55 days agoChange DetectedA new revision entry was added: Revision: v3.5.4, replacing the prior v3.5.3. This indicates a routine update to the Study Details page.SummaryDifference0.0%

- Check62 days agoChange DetectedThe update history now includes May 2026 entries (2026-05-08, 2026-05-07, 2026-05), while April 2026 entries (2026-04-22, 2026-04-09, 2026-04) were removed. These entries document when the page was updated, not changes to the study content.SummaryDifference0.1%

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.